CYP19A1 and neoplasm: Santen, et al. [213] hypothesized that by catalyzing the conversion of androgens to cancer-causing estrogens, the enzyme aromatase seems to contribute to the cause of breast cancer and that aromatase inhibitors would inhibit the process of tumor promotion by lowering tissue levels of estradiol and thus blocking cell proliferation.